Profile data is unavailable for this security.
About the company
Proteome Sciences plc is a specialist provider of contract proteomics services. The Company’s services enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic and therapeutic applications. SysQuant and TMT MS2 are unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents for multiplex quantitative proteomics.
- Revenue in GBP (TTM)5.03m
- Net income in GBP-2.44m
- Incorporated1993
- Employees35.00
- LocationProteome Sciences PLCCoveham House, Downside Bridge RoadADDLESTONE KT11 3EPUnited KingdomGBR
- Phone+44 20 7043 2116Fax+44 20 3637 7516
- Websitehttps://www.proteomics.com/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m |
Genflow Biosciences PLC | 0.00 | -1.63m |
Bivictrix Therapeutics PLC | 0.00 | -2.33m |
Cambridge Nutritional Sciences PLC | 9.05m | -3.21m |
ImmuPharma PLC | 69.96k | -2.99m |
Kanabo Group PLC | 895.00k | -7.99m |
Proteome Sciences plc | 5.03m | -2.44m |
Chill Brands Group PLC | 146.62k | -3.64m |
Provexis plc | 598.08k | -496.59k |
Abingdon Health PLC | 5.34m | -2.24m |
Shield Therapeutics PLC | 13.09m | -33.29m |
Synairgen plc | 0.00 | -9.99m |
Destiny Pharma PLC | 0.00 | -5.66m |
Genincode PLC | 1.72m | -6.73m |
LungLife AI Inc | 36.22k | -4.26m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Vulpes Investment Management Pte Ltd.as of 13 Apr 2023 | 67.79m | 22.97% |
Hargreaves Lansdown Asset Management Ltd.as of 01 Mar 2024 | 12.47m | 4.23% |
Jarvis Investment Management Ltd.as of 01 Mar 2024 | 8.92m | 3.02% |
ISPartners Investment Solutions AGas of 01 Mar 2024 | 4.24m | 1.44% |
James Brearley & Sons Ltd.as of 01 Mar 2024 | 3.33m | 1.13% |
Rowan Dartington & Co. Ltd. (Broker)as of 01 Mar 2024 | 2.20m | 0.75% |
Walker Crips Investment Management Ltd.as of 01 Mar 2024 | 1.56m | 0.53% |
IG Markets Ltd.as of 01 Mar 2024 | 1.35m | 0.46% |
J. M. Finn & Co. Ltd.as of 01 Mar 2024 | 813.00k | 0.28% |
HSBC Global Asset Management (UK) Ltd.as of 01 Mar 2024 | 652.00k | 0.22% |